HUYABIO International, LLC.
12 clinical trials · Sponsor
◉ Watch HUYABIO International, LLC.
| Record | Firm | Date |
|---|---|---|
| A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation (NCT05485974) | HUYABIO International, LLC. | 2022-08-01 |
| A Study of HBI-8000 (Tucidinostat) With Pembrolizumab in Non-Small Cell Lung Cancer (NCT05141357) | HUYABIO International, LLC. | 2022-02-15 |
| Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma (NCT04674683) | HUYABIO International, LLC. | 2021-08-12 |
| A Study of IV HBI-3000 for the Conversion Recent Onset Atrial Fibrillation (AF) (NCT04680026) | HUYABIO International, LLC. | 2021-06-01 |
| A Phase 1 Study of HBI-3000 (NCT03397641) | HUYABIO International, LLC. | 2017-10-17 |
Track HUYABIO International, LLC. automatically
Every clearance here is in the API, with alerts when new ones post.